Tìm theo
CDP323
Thuốc Gốc
Small Molecule
CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Cơ Chế Tác Dụng : CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. The mechanism of action of CDP323 is believed to rely on preventing immune cells to migrate from blood vessels through the vessel walls to reach various inflamed tissues, including the brain. This mechanism is thought to prevent overshooting immune reactions and subsequent tissue damage as seen during uncontrolled immune cell migration as in multiple sclerosis. CDP323 has the same mechanism of action as the monoclonal antibody natalizumab.
Chỉ Định : Investigated for use/treatment in multiple sclerosis.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05092
Wikipedia
http://en.wikipedia.org/wiki/CDP323
... loading
... loading